Art’s Call to Action
Publicado el enero 11th, 20261/11/26
Nov. 26, 2025 Exciting news this week: Altay Therapeutics’ DX5057 has received Orphan Drug status from the U.S. FDA. DX5057 is currently the only oral DUX4 inhibitor in development for […]
Archivado en: Vivir con FSHD